Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...

Teva is introducing the only generic version of Novartis AG's Sandostatin LAR Depot, in the United States. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe ...

Please provide your email address to receive an email when new articles are posted on . Most adults with acromegaly maintained or improved IGF-I levels with oral octreotide in three phase 3 trials.

PITTSBURGH, Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...

Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...

Trial in progress: A feasibility study of multi-platform profiling using biospecimens from patients with resected biliary tract cancer. This is an ASCO Meeting Abstract from the 2021 Gastrointestinal ...